Interactions between 2-fluoroadenine 9-β-D-arabinofuranoside and the kinase inhibitor UCN-01 in human leukemia and lymphoma cells

Clinical Cancer Research

Volumn 7, Issue 2, 2001, Pages 320-330

  Harvey, Sarah ^a   Decker, Roy ^a   Dai, Yun ^a   Schaefer, Gregory ^a   Tang, Lin ^a   Kramer, Lora ^a   Dent, Paul ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; FLUDARABINE;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CLONOGENESIS; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOMA CELL; MITOCHONDRION; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ARABINONUCLEOTIDES; BLOTTING, WESTERN; DRUG INTERACTIONS; DRUG SYNERGISM; ENZYME INHIBITORS; HL-60 CELLS; HUMANS; LEUKEMIA; LYMPHOMA; PHOSPHORYLATION; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-BCL-2; STAUROSPORINE; U937 CELLS; VIDARABINE;

EID: 0035120413     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Fludarabine phosphate: A new active agent in hematologic malignancies
2. Fludarabine: Pharmacokinetics, mechanisms of action, and rationales for combination therapies
3. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy
4. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity
5. Induction of apoptotic cell death in chronic lymphocytic leukemia cells by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine
6. Fludarabine- and gemcitabine-induced apoptosis: Incorporation of analogs into DNA is a critical event
7. Molecular and biochemical mechanisms of fludarabine and cladarabine resistance in a human promyelocytic leukemic cell line
8. Protein kinase C and lipid signaling for sustained cellular responses
9. 2arrest through a cdc2-dependent pathway that is associated with inactivation of the Weel Hu kinase and activation of the cdc25C phosphatase
10. 2checkpoint abrogation
11. UCN-01 in ovary cancer cells: Effective as a single agent and in combination with cis-diamminedichloroplatinum(II) independent of p53 status
12. 2checkpoint function in cancer cells with disrupted p53
13. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function
14. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2
15. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models
16. 1-acid glycoprotein in humans
17. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
18. Old and new therapies in chronic lymphocytic leukemia: Now is the time for a reassessment of therapeutic goals
19. Induction of apoptosis and differentiation by fludarabine in human myelomonocytic leukemia cells (U937): Interactions with the macrocyclic lactone bryostatin 1
20. Agents that downregulate or inhibit protein kinase C circumvent resistance to 1-β- D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells overexpressing Bcl-2
21. WAF1/CIP1increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis
22. An analytical system for rapid separation of tissue nucleotides at low pressures on conventional anion exchangers
23. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
24. Protein kinase inhibitors flavopiridol and 7-hydroxystaurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia
25. UCN-01, an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily
26. The Chk1 protein kinase and the Cdc25C regulatory, pathways are targets of the anticancer agent UCN-01
27. Enhancement of antitumor activity of mitomycin C in vitro by UCN-01, a selective inhibitor of protein kinase C
28. 7-hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells
29. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells
30. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: A cautionary note
31. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells
32. Apoptosis, p53, and tumor cell sensitivity to anticancer agents
33. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells
34. Effects of bryostatin 1 and rGM-CSF on the metabolism of 1-β-D-arabinofuranosylcytosine in human leukaemic myeloblasts
35. Phase I trial of the PKC activator bryostatin 1 (NSC339555) and F-ara-AMP (fludarabine) in patients with progressive CLL and refractory indolent non-Hodgkin’s lymphoma
36. 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma
37. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report
38. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: Presentation of a novel therapeutic paradigm